No federal rule says who must review a company-run study in client-owned pets. 21 CFR 511.1, the rule for investigational animal drugs, names no ethics committee, and a company that neither buys nor transports the animals and takes no federal research money is not a research facility under the Animal Welfare Act, the status that brings an IACUC. Review still happens, because teaching hospitals and journals ask for it and good clinical practice asks the sponsor to weigh animal welfare first. The reviewer is the site's own board when the study runs at a veterinary school, or a committee the sponsor convenes or contracts on the IACUC pattern: at least three people, one a veterinarian and one with no tie to the company. They need to see the protocol, the owner consent form and everything else owners will read, the safety plan, and the status of the product.
Is a committee required?
21 CFR 511.1(b) lets a new animal drug ship for clinical investigation once its conditions are met: investigational labelling, a "Notice of Claimed Investigational Exemption for a New Animal Drug" filed before shipment (b)(4), complete records (b)(7), and monitoring and hazard reports by the sponsor (b)(8). It mentions no IACUC, ethics committee or owner consent.
The IACUC comes from the Animal Welfare Act. Under 9 CFR 1.1, a research facility uses live animals in research "and that (1) purchases or transports live animals in commerce, or (2)" receives federal research funds. Only a research facility must keep a committee under 9 CFR 2.31. A sponsor whose study animals stay with their owners and their own veterinarians usually meets neither condition, and the instructions to APHIS Form 7023, USDA's annual report for research facilities, say "DO NOT include animals used in clinical trials in the context of a Veterinary- Client relationship." A federal grant changes the answer. Have counsel confirm your own facts.
Guidance #85 (VICH GL9), FDA's good clinical practice standard, names no committee either. It asks investigator (3.2.12) and sponsor (4.2.17) to comply with "applicable regulatory requirements governing the humane care of study animals", and the sponsor to determine that there are "no environmental, animal welfare, or scientific grounds which might preclude the conduct of a clinical study" (4.2.1). CVM's draft Guidance #282 (September 2023, not final) notes "there are no Federal laws that regulate the informed consent process" for investigational drug studies in client-owned companion animals (V.A), yet recommends a consent form for every study with client-owned dogs, cats or horses (I). An outside review puts that 4.2.1 judgment on record.
Who can review the study?
- The site's board. At a veterinary teaching hospital the choice is made for you. UC Davis's Clinical Trial Review Board advises the IACUC and "will pre-review all protocols involving VMTH patients", and a clinical trial's protocol must "include an attached owner informed Consent Form." Texas A&M's Clinical Research Review Committee reviews a study when "non-residual sample collection, diagnostics, treatment, or animal care is influenced by considerations other than the needs of the patient", and asks for the animal use protocol and consent form five weeks before its meeting.
- A committee you convene. Borrow 9 CFR 2.31(b): a chair and at least two more members, at least one a veterinarian, and at least one "not affiliated in any way with the facility". For a sponsor, that is a veterinarian outside the study team and a member from outside the company. Write down how a member with a stake in the result steps aside, and keep minutes and a signed approval letter.
- A committee you contract. An independent animal ethics committee, or another institution's IACUC that takes outside protocols. Ask for its membership, its conflict policy and how it handles amendments and adverse events after approval.
For a study meant for FDA, GL9 6.2 encourages the regulator's review of the protocol before the study starts, and draft #282 section VII asks a sponsor seeking concurrence on its consent form to submit it with the protocol. A journal may ask at the end: Frontiers' policy asks authors to "confirm that written informed consent has been granted by the owner(s)", and wants research with regulated animals "reviewed and approved by an ethics committee prior to commencing the study".
What reviewers need to see
| What to send | What it should show | From |
|---|---|---|
| The protocol, signed and dated by sponsor and investigator, with its number, status and version date | Objective, design, randomization and blinding, inclusion, exclusion and removal criteria, doses and why, endpoints, statistics and sample size | GL9 1.29, 6.3 |
| A description of the animal use | Species and approximate number, why animals and why that number, each procedure, how pain and distress are kept to what is unavoidable, any euthanasia method | 9 CFR 2.31(e) |
| The owner consent form | That the study's purpose is not treatment; the groups and the chance of control; alternatives; owner duties and costs; procedures outside usual care; risks; withdrawal without penalty; confidentiality, including that FDA may inspect; contacts | Draft #282 VI |
| Everything else owners read | Recruitment text, visit schedule, diary instructions | GL9 6.3.20.3 |
| The safety plan | How often animals are checked, what is done on an adverse event (including breaking the blind), how it is recorded and reported, care for animals removed from the study | GL9 6.3.19, 6.3.15.2 |
| The product's status | Approved and used as labelled, or unapproved with the 511.1 notice filed | 21 CFR 511.1(b)(4) |
An IACUC-style committee then applies 9 CFR 2.31(d)(1): procedures that "avoid or minimize discomfort, distress, and pain", pain relief for painful procedures, and medical care from a qualified veterinarian.
How does the design change the answer?
- Observational, nothing assigned. No FDA filing, and GL9 2.6 puts studies "not intended to be used for regulatory support" outside its scope. A site board may still want review when the study adds anything to usual care; by Texas A&M's test, one extra blood draw for the study is enough. Draft #282 still recommends a consent form.
- An approved product given as its label directs. No investigational filing for the product. The review turns on what the study adds: procedures, a control group, the consent form. If the data are meant for FDA, GL9 is the standard for the conduct.
- An unapproved product. The sponsor files the 511.1(b)(4) notice before the product ships. The consent form should state that the product "is investigational, and safety and effectiveness have not been demonstrated" (#282 VI.A.1.a), and the sponsor may not represent it as safe or effective for the use under investigation (511.1(b)(8)(iv)). Expect close reading of the risks and of human user safety (#282 VI.E).
What stays with the sponsor and the investigator?
They write the protocol, choose the reviewer and answer its questions, keep the approval letter and its conditions, write the consent content, file the 511.1 notice where it applies, and report adverse events and hazards. Send each protocol amendment back to the reviewer before it takes effect. GL9 4.3.1 keeps "ultimate responsibility for the quality and integrity of the study data" with the sponsor. A data system cannot approve a study or decide what owners are told.
Where Signalment fits
Signalment is a data system for running the study once it is approved. Protocol and consent are versioned, and owners can sign consent on their own phone, each signature bound to the exact version of the text they read, so a reviewer can match signatures to the approved version. Team signatures re-check the signer's password, changes go on an append-only, hash-chained audit trail, and the workspace carries a compliance guide covering INAD, IACUC, VICH GL9 and 21 CFR Part 11. It does not review or approve studies, keep a committee or write consent content, and drug accountability ledgers are not built yet. The sponsor's view is at signalment.app/sponsors; for the form itself, see Informed consent for client-owned animal studies.
Sources
- 21 CFR 511.1, new animal drugs for investigational use: https://www.ecfr.gov/current/title-21/section-511.1
- 9 CFR 1.1, definitions: https://www.ecfr.gov/current/title-9/section-1.1
- 9 CFR 2.31, Institutional Animal Care and Use Committee: https://www.ecfr.gov/current/title-9/section-2.31
- USDA APHIS Form 7023, Annual Report of Research Facility, with instructions (July 2020): https://www.aphis.usda.gov/sites/default/files/APHIS_7023.pdf
- FDA Guidance #85, VICH GL9, Good Clinical Practice: https://www.fda.gov/media/70333/download
- FDA CVM draft Guidance #282, Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals (September 2023): https://www.fda.gov/media/172056/download
- University of California, Davis, Office of Research, VMTH Clinical Trials: https://research.ucdavis.edu/research-support/animal-care-use/iacuc/vmth-clinical-trials/
- Texas A&M College of Veterinary Medicine, Clinical Research Review Committee: https://vetmed.tamu.edu/research/clinical-trials/crrc/
- Frontiers, Policies and publication ethics: https://www.frontiersin.org/guidelines/policies-and-publication-ethics